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restraints and objections about the viability of the fund are still a matter of debate,
focused particular on the development of a flexible mechanism for primary health
care that will ensure equitable access and benefits for members and improve the
quality of services.
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OBJECTIVES: Price capping of generics against the originator (also known as price
linkage) has been in use for some time despite studies questioning its efficacy as a
cost-containment mechanism. In particular, a 2007 study from Norway – where
internal reference and generic price linkage to the originator co-existed for some
time - found that both originator and generic prices fell significantly, but the price
decline impact was sharper for originator drugs in the reference pricing group than
in the price caps group. This study seeks to evaluate if price capping remains a
policy of choice in the current austerity climate. METHODS: Research focused on a
review of current pricing and reimbursement (P&R) regulations for generics in
European Union countries and major markets outside the EU to identify which
countries have adopted or are in the process of adopting new price caps or have
amended existing price caps for generics versus the originator from the start of
2010 to date. The review includes both original laws related to price capping and
interpretation of the place of price linkage in each country’s pharmaceutical P&R
system from secondary sources and from IHS Global Insight’s proprietary Same
Day Analysis archive. RESULTS: France, Portugal, Hungary, the Czech Republic,
Romania, Slovakia, Greece, Japan and Canada are among the countries which have
recently amended their use of price linkage in an attempt to contain pharmaceu-
tical spending.CONCLUSIONS:While price caps remain popular, it is rare for coun-
tries to use them in isolation. Internal reference pricing is typically also in use.
Among countries which have recently made changes to their price linkage system,
Romania, Hungary and Poland have also undertaken changes to their internal
reference pricing system, as governments attempt to tackle the cost-containment
paradigm from all sides.
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OBJECTIVES: To analyze the influence of regulatory changes for medicines pricing
and reimbursement on medicines prices. METHODS: Regulatory analysis was per-
formed towards the Drug Law, Regulation on positive drug list (PDL), and on med-
icines reimbursement rules. All medicines affected by the changes were system-
ized by the way of dispensing and financing. Comparative analysis of the changes
in medicines prices before and after 30 of March 2011 was developed as well a year
later for absolute and relative change of the prices. RESULTS: The pricing and
reimbursement processes are controlled by the Pricing and reimbursement com-
mittee within MoH. Medicines are separated in two groups according to their price
control – with registration of maximal retails prices for OTC and out of the reim-
bursement list (30 days procedure); and regulation of prices for publicly financed
medicines (60 days procedure) by inclusion into the PDL. In the beginning of 2011
the Ministry council initiated regulatory changes. 150 INN of medicines that were
financed via the centralized procurement procedures organized by the MoH were
separated in 2 groups. 82 INN for outpatient care were transferred to national
health insurance fund (NHIF) and 68 for inpatient care to hospitals. For the 82 INN
were changed not only the procurement and financing institution but also the way
of prices establishment through regulated as reference prices with regressive mar-
gins. Only 5 medicines decrease their prices after the transformation, but a year
later all medicines decreased their prices. For the medicines transferred to hospi-
tals the biggest hospitals managed to contract lower prices than before but small
ones were unable to do so. In general total cost of the supplied medicines weighed
by quantity procured was lower than before the changes. CONCLUSIONS: Regula-
tory changes led to positive economic impact but still the long term consequences
remain unclear for all medicines.
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OBJECTIVES: Patient access schemes (PAS) are commonly used in the UK as a way
to reduce a drug’s Incremental Cost Effectiveness (ICER) per Quality Adjusted Life
Year (QALY) ratio and gain NICE acceptance without reducing the list price. With
the advent of value based pricing (VBP) in 2014, the role of PAS is expected to
change. This study examines if PAS will continue to be used in the UK after VBP is
introduced and what their role is likely to be. METHODS: Stakeholders involved in
the current NICE health technology assessment process were interviewed to un-
derstand how PAS use may evolve following the introduction of VBP. Secondary
research was conducted of government proposals for VBP implementation, the
NICE response to VBP consultation and the current usage of PAS in the UK based on
NICE assessments and data from the IHS Global Insight Risk Sharing database.
RESULTS: With the advent of VBP, the price of a drug should in principle reflect its
value taking into account the level of uncertainty related to its efficacy. All drugs
that pass the VBP test should, in theory, be reimbursable, thus, eliminating the
need for a PAS that adjusts the cost of treatment allowing it to meet the UK’s ICER
per QALY threshold. Contrary to these expectations, primary research indicates
that PAS would continue to be used as payers attempt to secure a price lower than
the NICE-set VBP. CONCLUSIONS: PAS would remain a fact of life in the UK even
after VBP is implemented. This would apply not only for older drugs launched
before VBP, but also for new drugs and new indications marketed post-2013 be-
cause payers are expected to see the NICE-established VBP as a recommended
maximum price and attempt to negotiate that down through a PAS.
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OBJECTIVES: Defining and applying decision criteria are key to accountability and
reasonableness in decisionmaking and to ensure the most beneficial allocation of
health care resources. Objectives were to gather data on criteria considered by
policy and clinical decisionmakers in health care decisions globally.METHODS:An
online questionnaire was developed with 43 criteria organized into 10 clusters.
Using snowball sampling, decision makers were invited by an international task
force to report which criteria they consider and how these criteria weighed when
making decisions on health care interventions in their context. For each criterion,
respondents reported “currently considered”, “should be considered” and weight
assigned. Differences in proportions of participants reporting consideration of
each criterion were explored with inferential statistics across levels of decision
(micro, meso, macro), decision-maker perspective, and world region. RESULTS: A
total of 140 decision makers (1/3 clinical, 2/3 policy) from 23 countries in five con-
tinents completed the survey. Most relevant criteria (top ranked for “Currently
considered”, “Should be considered” and weights) were Clinical efficacy/effective-
ness, Safety, Quality of evidence, Disease severity and Impact on health care costs.
Organizational and skill requirements ranked high for consideration but low for
weights. For a majority of criteria, the number of decision makers reporting that
they ‘should be considered’ was higher than that reporting they are currently con-
sidered (P0.05). For more than 75% of criteria, there were no statistical differences
in proportions across levels of decision, perspective and world region. Differences
in proportions across several comparisons were statistically significant for criteria:
Population priorities, Stakeholder pressure/interests, Capacity to stimulate re-
search, Impact on partnership and collaboration, and Environmental impact
(P0.05). CONCLUSIONS: Results suggest a significant international agreement
among decision makers on the relevance of a core set of normative and feasibility
criteria and on the need to consider a wider range of criteria in decision-making
processes. Areas of divergence appear to be principally related to contextual as-
pects.
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OBJECTIVES: Since 2011, pharmaceutical companies have to submit a benefit as-
sessment dossier for new drugs in Germany. The dossier must contain information
about the additional benefit to an appropriate comparative therapy (ACT), costs
and the potentially targeted patient population. This work’s aim is to display the
challenges in collecting the information for Xiapex®, approved for treatment of
Dupuytren’s contracture in patients with a palpable cord, which was compared to
limited fasciectomy.METHODS:A systematic literature review, national and inter-
national, was used to determine epidemiological figures and cost data. Where no
information was available, necessary data was assessed from claim data. To deter-
mine the percentage of patients with palpable cord a Delphi study was conducted
with office based hand surgeons and orthopaedists. RESULTS: No valid data basis
was found for national epidemiological figures. Estimations based on European
prevalence data (1,7%-2,4%) lead to 1,34-1,9 Mio. Germans affected by Mb. Du-
puytren. Thereof, approx. 35.800 surgeries are conducted in Germany per year. The
Delphi-study revealed an estimation of 53,5% patients with palpable cord, resulting
in 19.153 patients eligible to Xiapex® treatment. No literature was found for treat-
ment costs of Mb. Dupuytren. Actual costs (inpatient and outpatient care plus
additional costs) were therefore selected from available claim data resulting in a
weighted average of 2087,58€ per patient and year. CONCLUSIONS: With a surgical
procedure as ACT, dossier developers have to face challenges due to the lack of
transparent, publically available data. Best available sources were used to gather
the information needed. The fact that the German IQWiG challenged our data
within the benefit assessment process without being able to provide better sources
of information underlines the necessity of an improvement regarding the availabil-
ity and open access to suitable data. This will increase validity of data in the
required dossier for an informed consequent decision making.
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OBJECTIVES: Health policy chances may effect the conducted studies in all fields.
Pharmacoeconomics dossiers for the reimbursement applications for new medi-
cines were not mandatory before year 2008. New molecules need to show cost-
effectiveness and possible budget effect with their applications for reimbursement
to Social Security Institution from 2008. This policy changing may effect pharmaco-
economics and health outcome studies in Turkey. The aim of the study is to eval-
uate the improvement of pharmacoeconomics and health outcome studies which
are specific for Turkey in years. METHODS: Database of ISPOR Outcome Research
Digest were searched online from the begining of database (1998) to 2011 with the
key words “Turkey” and “Turkish”. The inclusion criteria were taken as study must
be specific for Turkey. Included abstract evaluated for increasing abstract numbers
in years, distribution in study topics and diseases areas. RESULTS: A total of 108
abstracts were searched from the database; 80 of them were matched with inclu-
sion criteria. First abstracts were published in 2000. There were only one or two
abstracts per year until 2008. After year 2008, published abstracts numbers were
increased year by year and reached up to 18 per year in 2011. 55% of all abstracts
were Cost Studies(CS). It was followed by Health Care Use & Policy Studies(HP)
(13.7%) and Conceptual Papers (CP) (8,7%). 15% of all abstracts were Multipl Disease
studies. It was followed by Mental Health (15%) and Allergy(12.5%). CONCLUSIONS:
It was shown that the policy changing in 2008 as to require pharmacoeconomics
dossiers in the reimbursement application effected Turkey specific pharmacoeco-
nomic and health outcome studies positively. In other words, pharmaceutical ýn-
dustry and the government started to invest in pharmacoeconomics and health
outcome studies after 2008.
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OBJECTIVES: To analyze real occurrences of drug shortages throughout 2010 and
2012 and the underlying reasons. METHODS: We conducted a systematic search in
the scientific literature, media and public domain on occurrences of drug shortages
and the perceived underlying reasons. The type of drug shortages were categorized
and considered in context to their impact on access to medicines and health care
system efficiency. RESULTS: While there were 20 publications of any type around
this subject in Pubmed in 1995, the number increased with 34 in the year 2000, 70 in
2005, 99 in 2010, and 128 in 2011. The publications have discussed the health con-
sequences, workarounds, and the health consequences of the workarounds. In
February 2012, 110 drugs were listed on the FDA Web site, including at least 14
commonly used cancer chemotherapy drugs. Likewise, drug shortages are re-
ported in many countries around the world including European countries such as
Spain, France, UK, Russia, Portugal, Greece, or Rumania. Over the years, the reasons
for drug shortages have changed from being predominantly caused by shortages in
the active ingredients or insufficient distribution systems to currently often being
the consequences of strong cost-containment measures or economic crisis.
CONCLUSIONS: Drug shortages are increasingly observed over the last decade.
Drug shortages can have multiple reasons and are currently often induced by eco-
nomic or cost-containment reasons, and to misaligned incentives in the supply
chain.
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OBJECTIVES: The main hypothesis in this study is that stakeholders have different
preferences concerning IT innovations in hospitals, and these preferences are
caused by perceived cost/benefit ratios. This will translate in disagreement be-
tween stakeholders on which innovations to implement first, possibly explaining
the slow diffusion of innovations in health care. METHODS: Analytic Hierarchy
Process (AHP) was used to quantify stakeholders positions in their priority of nine
IT innovations. These innovations were selected after a systematic literature re-
view and expert interviews. In the AHP, decision criteria related to costs and ben-
efits of the innovations were defined: improvement in efficiency, health gains,
satisfaction with care process, and required investments. Stakeholders judged the
importance of the decision criteria and prioritized the selected IT innovations ac-
cording to their expectations of how well the innovations would perform on these
decision criteria. RESULTS: Sixty-two respondents, including patients, nurses,
physicians, managers, health care insurers and policy makers showed significant
differences in their expectations about their respective costs and benefits of the
innovations, resulting in diverging preferences for the health care innovations. For
instance, self tests are one of the most preferred innovations by health care insur-
ers and managers, due to its expected positive impacts on efficiency and health
gains. However, physicians, nurses and patients strongly doubt the health gains of
self tests, and accordingly rank self tests as the least preferred innovation.
CONCLUSIONS: We found clear differences in expectations of different stake-
holder groups on IT innovations. The differences can be understood from the per-
spective of costs and benefits per stakeholder for each innovation. This study gives
a first quantitative insight in stakeholder differences and presents a novel way to
study stakeholder differences. The results may be used by decision makers to
include alignment of stakeholder positions in implementation processes.
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OBJECTIVES: Clinical studies are the main drivers of innovation in drug research.
Pharmaceutical companies invest 15-20% of their revenue to clinical research for
developing new treatments. Due the high investment opportunities, countries take
actions to obtain the maximum share from global clinical studies market. Turkey
has a good potential due the geological location. The aim of the study is to show
possible economic effect of clinical studies to Turkey. METHODS: Application doc-
uments/files for the Ethic Committee of Istanbul Medical Facultyy were examined
from 2006 to 2010. Studies sponsored by pharmaceutical companies were included.
Pharmaceutical companies estimated budgets were accounted. Distribution of dif-
ferent disease areas of the studies and budgets were evaluated. RESULTS: Total
number of applications for clinical studies have risen from 177 to 252 from 2006 to
2010. All industry sponsored clinical trials were reported as 184 for the given time-
line. Approved sponsored pharmaceutical trials estimated total budget was € 859
million and Istanbul Medical Faculty could take € 59 million of all estimated budget
in given timeline. Average cost for per clinical trial and per patient were calculated
as € 467k and € 5k for Turkey. The highest estimated budget was hold by cardiolog-
ical trials with € 61 million, followed by oncology and norology with € 59 million for
the given timeline. CONCLUSIONS: It was shown that clinical trials may have a
great impact to Turkey‘s economy. If Turkey may increase new launched trials, this
is an opportunity for Turkey to take extra investment. Because these number are
below the potential of pharmaceutical trials investment amounts when compared
total pharmaceutical market. In addition, it is needed to account possible effects to
reimbursement agencies. Due the potential impact of clinical studies for Turkey,
decision and policy makers need to take action to improve clinical studies in Tur-
key.
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OBJECTIVES: To use a database of previous National Institute for Health and Clin-
ical Excellence (NICE) health technology assessment (HTA) decisions (HTA
inSite)1to understand the impact of four clinical evidence scenarios on the out-
come of NICE technology appraisals (TAs). METHODS: We identified published
NICE TAs containing evidence applicable to the following scenarios: 1) Efficacy data
with a non-significant but positive trend; 2) Surrogate endpoints used in place of
real endpoints; 3) Composite endpoints where statistical significance was driven by
some, but not all, of the individual components; and 4) Efficacy data from observa-
tional studies. For each scenario, multiple submissions and re-submissions were
identified using HTA inSite. The analysis focused on the evidence submitted, the
final decision and critique by NICE, and any changes in approach by the manufac-
turer at re-submission. RESULTS: Clear patterns emerged for each scenario. For
example NICE accepted data from surrogate endpoints (scenario 2) in all of the 4
submissions analysed. This was due to support by clinical experts and a clear
rationale for the surrogates as established markers of efficacy. Observational data
(scenario 4) were accepted in the absence of randomised controlled trials (RCTs), or
in addition to RCTs where long-term or country-specific evidence was required.
However, it was important to acknowledge and report any potential bias associated
with the design of observational studies. CONCLUSIONS: An evaluated database
can be used to understand the impact of any clinical evidence scenario on NICE
decisions. The results can be used to inform submission strategy and assess deci-
sion outcome risk.
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OBJECTIVES: One priority for improving Russian health care is the optimization of
health care resource use. Pharmacoeconomic (PE) methods allow economic evalu-
ation of pharmaceutical products and services. The objective of this study was to
investigate the extent of PE education in 2012 across pharmacy schools/depart-
ments in Russia. METHODS: A survey was e-mailed to 47 pharmacy schools listed
on the federal educational portal www.edu.ru. Follow-up phone calls were made to
non-respondents. Questions were used to determine: whether PE topics were
taught and under what discipline, whether it was a required (base) or elective
(variable) course, the number of academic hours dedicated to PE, the number of
students in the course, topics covered, resources used, an opinion of the instructor
on the sufficiency of the number of hours devoted to PE, and suggestions on PE
education improvement in pharmacy schools. RESULTS: Forty-three schools re-
plied to the survey (91.5% response rate). PE education was offered at 35 (81%)
schools of pharmacy: in 25 (58%) schools PE topics were covered under required
(base) course with median number of hours 3 (range 0.5-10, mean4) and in 10
(23%) schools PE topics were covered under elective (variable) course with median
number of hours 31 (range 16-54, mean32). Eight (19%) pharmacy schools did not
teach PE. The median numbers of students taking PE were 36 (range 12-220,
mean42) and 53 (range 24-350, mean86) for required (base) and elective (vari-
able) courses respectively. The majority of the instructors 22(63%) noted insuffi-
ciency of hours dedicated to PE. CONCLUSIONS: The majority of Pharmacy schools
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